Literature DB >> 15526345

Proteome analysis of human substantia nigra in Parkinson's disease.

Manuela Basso1, Sabrina Giraudo, Davide Corpillo, Bruno Bergamasco, Leonardo Lopiano, Mauro Fasano.   

Abstract

Protein expression has been compared in human substantia nigra specimens from Parkinson's disease (PD) patients and from controls, and 44 proteins expressed in this midbrain region were identified by peptide mass fingerprinting. Among them, nine showed changes in their abundance. L and M neurofilament chains are less abundant in PD specimens, whereas peroxiredoxin II, mitochondrial complex III, ATP synthase D chain, complexin I, profilin, L-type calcium channel delta-subunit, and fatty-acid binding protein are significantly more present in PD samples than in controls. Besides the consolidated view of oxidative stress involvement in PD pathogenesis, suggested by overexpression of mitochondrial and reactive oxygen species (ROS)-scavenging proteins, these results indicate a possible potentiation mechanism of afferent signals to substantia nigra following degeneration of dopaminergic neurons.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15526345     DOI: 10.1002/pmic.200400848

Source DB:  PubMed          Journal:  Proteomics        ISSN: 1615-9853            Impact factor:   3.984


  78 in total

1.  Nuclear translocation of anamorsin during drug-induced dopaminergic neurodegeneration in culture and in rat brain.

Authors:  Kyung-Ah Park; Nuri Yun; Dong-Ik Shin; So Yoen Choi; Hyun Kim; Won-Ki Kim; Yuzuru Kanakura; Hirohiko Shibayama; Young J Oh
Journal:  J Neural Transm (Vienna)       Date:  2010-10-06       Impact factor: 3.575

Review 2.  Biomarkers for cognitive impairment in Parkinson disease.

Authors:  Min Shi; Bertrand R Huber; Jing Zhang
Journal:  Brain Pathol       Date:  2010-05       Impact factor: 6.508

3.  Edaravone leads to proteome changes indicative of neuronal cell protection in response to oxidative stress.

Authors:  Mohammad-Saeid Jami; Zahra Salehi-Najafabadi; Fereshteh Ahmadinejad; Esthelle Hoedt; Morteza Hashemzadeh Chaleshtori; Mahdi Ghatrehsamani; Thomas A Neubert; Jan Petter Larsen; Simon Geir Møller
Journal:  Neurochem Int       Date:  2015-07-29       Impact factor: 3.921

Review 4.  Proteomics of the human brain: sub-proteomes might hold the key to handle brain complexity.

Authors:  F Tribl; K Marcus; G Bringmann; H E Meyer; M Gerlach; P Riederer
Journal:  J Neural Transm (Vienna)       Date:  2006-07-13       Impact factor: 3.575

Review 5.  Reverse genetics for proteomics: from proteomic discovery to scientific content.

Authors:  M Bauer; M Ueffing
Journal:  J Neural Transm (Vienna)       Date:  2006-07-13       Impact factor: 3.575

Review 6.  Translational research in central nervous system drug discovery.

Authors:  Orest Hurko; John L Ryan
Journal:  NeuroRx       Date:  2005-10

Review 7.  Neuroproteomics as a promising tool in Parkinson's disease research.

Authors:  Ilse S Pienaar; William M U Daniels; Jürgen Götz
Journal:  J Neural Transm (Vienna)       Date:  2008-06-04       Impact factor: 3.575

8.  Membrane-associated farnesylated UCH-L1 promotes alpha-synuclein neurotoxicity and is a therapeutic target for Parkinson's disease.

Authors:  Zhihua Liu; Robin K Meray; Tom N Grammatopoulos; Ross A Fredenburg; Mark R Cookson; Yichin Liu; Todd Logan; Peter T Lansbury
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-04       Impact factor: 11.205

9.  FABP3 protein promotes α-synuclein oligomerization associated with 1-methyl-1,2,3,6-tetrahydropiridine-induced neurotoxicity.

Authors:  Norifumi Shioda; Yasushi Yabuki; Yuka Kobayashi; Misaki Onozato; Yuji Owada; Kohji Fukunaga
Journal:  J Biol Chem       Date:  2014-05-22       Impact factor: 5.157

Review 10.  Nrf2--a therapeutic target for the treatment of neurodegenerative diseases.

Authors:  Delinda A Johnson; Jeffrey A Johnson
Journal:  Free Radic Biol Med       Date:  2015-08-14       Impact factor: 7.376

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.